Atea Pharmaceuticals Files 2024 DEF 14A
Ticker: AVIR · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1593899
| Field | Detail |
|---|---|
| Company | Atea Pharmaceuticals, Inc. (AVIR) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, governance
TL;DR
Atea Pharma's 2024 proxy statement is out, detailing exec pay and stock awards.
AI Summary
Atea Pharmaceuticals, Inc. filed its DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate governance matters. Key financial data for the fiscal years 2020 through 2024 are presented, including information on stock awards and option awards for both PEO and Non-PEO NEO members.
Why It Matters
This filing provides crucial insights into how Atea Pharmaceuticals compensates its top executives, which can influence investor decisions and the company's strategic direction.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine but can reveal changes in executive compensation or governance that may impact stock performance.
Key Numbers
- 2024 — Fiscal Year (Reporting period for executive compensation details.)
- 2020-2024 — Financial Data Range (Includes historical data for compensation analysis.)
Key Players & Entities
- Atea Pharmaceuticals, Inc. (company) — Filer
- 20250429 (date) — Filing Date
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used to solicit proxies from shareholders for an upcoming annual meeting, providing information on matters to be voted on, such as director elections and executive compensation.
Who are the PEO and Non-PEO NEO members mentioned in the filing?
PEO (Principal Executive Officer) and Non-PEO NEO (Non-Principal Executive Officer Named Executive Officers) refer to the company's top executives whose compensation is detailed in the filing.
What types of awards are detailed in the filing?
The filing details stock awards and option awards granted to executive officers.
What is the fiscal year end for Atea Pharmaceuticals, Inc.?
The fiscal year end for Atea Pharmaceuticals, Inc. is December 31.
When was this DEF 14A filing submitted?
This DEF 14A filing was submitted on April 29, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Atea Pharmaceuticals, Inc. (AVIR).